Having trouble accessing articles? Reset your cache.

MM-121: Phase II data

Top-line data from a cohort of NSCLC patients whose disease progressed after EGFR therapy (n=50) in a single-arm, open-label, international Phase II trial showed that MM-121 plus Tarceva erlotinib missed

Read the full 301 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE